Rarer HCV Types Still Need Attention
Genotype 1 most common, but others also appear in U.S.
Contributing Writer, MedPage Today
Direct-acting agents (DAAs) have been so effective for genotype 1 that success rates have skyrocketed. Encouragingly, genotype 4 tends to also respond well to these agents. And, work continues on DAAs with newer antiviral agents showing excellent action on non-genotype 1 versions of HCV.....
When compared with other HCV patients, genotype 3 patients are relatively difficult to treat, especially those with cirrhosis. However, studies with sofosbuvir-velpatasvir are "encouraging, with SVR [sustained virologic response] rates of 97% in treatment-naïve patients and 90% in treatment-experienced patients."
Feb 16, 2017
HCV Genotype 1 No Longer a Treatment Bugbear
- Newly Diagnosed
- All FDA Approved Drugs To Treat Hepatitis C
- 2017-HCV Genotypes/Treatment
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Not FDA Approved - Sofosbuvir/Velpatasvir/Voxilaprevir
- Not FDA Approved - Glecaprevir/Pibrentasvir (G/P)
- NOT FDA Approved - MK3 (MK-3682/grazoprevir/ruzasvir1)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- FibroScan® Understanding The Results
- Is There A Natural Way To Improve Liver Fibrosis?
- Staging Cirrhosis